USPTO Patent Applications - Therapeutics (A61P)

Protein or Polypeptide-Loaded Extracellular Vesicle Delivery Platform and Application Thereof

USPTO published patent application US20260108470A1 on April 23, 2026, disclosing a plasmid combination for preparing extracellular vesicles loaded with target proteins or polypeptides, including cGAS and Cre gene plasmids. The application, filed on December 21, 2025 (Application No. 19428281), also covers the extracellular vesicles loaded with these proteins and their use in cancer prevention or treatment. Inventors are Linzhao Cheng, Senquan Liu, and Ding Ma.

Cyr61 in Carbon Nanotubes Restores Bone Density

The Board of Regents of the University of Texas System has filed Application US20260108472A1 for methods and compositions using recombinant Cyr61 carried in carbon nanotubes to restore Cyr61 expression in bone, increase bone density, and treat bone disease. The application was published April 23, 2026 with inventors Xiao-Dong Chen, Milos Marinkovic, and Qiuxia Dai. No compliance obligations or enforcement actions are associated with this patent application publication.

Hemorrhage Prevention Compounds Patent Application

Jesus E. VILLAFRANCA, Charles Richard KISSINGER, and Guohong LI filed Application US20260108481A1 on December 12, 2025, for compounds and methods for the prevention and treatment of hemorrhage and vascular instability. The application, which relates to therapeutic compounds potentially induced by thrombolytic and anti-coagulant therapies, was published on April 23, 2026. The invention is classified under CPC codes including A61K 31/167, A61K 38/482, and A61P 7/04.

PAMAM Nanoparticle Degrades MDM2 and GLUT1 Proteins

USPTO publishes patent application US20260108474A1 for a PAMAM-based nanoparticle protein degradation system targeting MDM2 and GLUT1 proteins for cancer therapy. Invented by Yingshu Guo and Wennan Yan, the system uses silica nanoparticle cores coated with poly(amidoamine) dendrimers linked to three small-molecule ligands. Filed December 19, 2025 and published April 23, 2026, the application claims a cooperative degradation strategy that suppresses tumor cell proliferation and stabilizes p53 protein.

Cyclobenzaprine 5.6mg Daily Transmucosal Fibromyalgia Treatment Patent

USPTO published application US20260108477A1, filed December 16, 2025 (Application No. 19421039), discloses methods for treating fibromyalgia using 5.6mg cyclobenzaprine HCl daily via transmucosal administration in a eutectic form with a basifying agent. The application names Seth Lederman and Gregory M. Sullivan as inventors. CPC classifications include A61K 31/135 (quinoline/dihydroquinoline compounds) and A61P 25/00 (nervous system disorders).

Mitochon Pharmaceuticals 2,4 DNP Cancer Treatment Patent Application

Mitochon Pharmaceuticals, Inc. has filed patent application US20260108476A1 covering compositions and methods for treating cancer using 2,4-DNP (dinitrophenol) and prodrugs thereof. The application, originally filed on August 4, 2022 (Application No. 18681016), was published on April 23, 2026. Named inventors include John Gerard Geisler, Robert Alonso, and Marcelo G. Bonini. The CPC classifications indicate therapeutic applications across multiple drug compound categories (A61K 31/06 through A61P 35/00).

2,3-Dimethoxyquinone Compositions for Preventing Diabetic Retinopathy

USPTO published patent application US20260108483A1 on April 23, 2026, covering methods, compositions, and kits containing substituted 2,3-dimethoxyquinone (Formula I) or a pharmaceutically acceptable salt for preventing progression of diabetic retinopathy, diabetic macular edema, and related retinal disorders. The application names four inventors: Mitchell George Brigell, Ronil Ajaykumar Patel, Jay Stuart Pepose, and Mina Sooch. Filed July 24, 2025 under application number 19279680, the invention is classified under CPC codes A61K 31/192, A61P 9/10, and A61P 27/02.

Mitoxantrone Hydrochloride Liposome for Neuromyelitis Optica Spectrum Disorders Treatment

The USPTO published patent application US20260108478A1 on April 23, 2026, covering mitoxantrone hydrochloride liposome compositions for treating neuromyelitis optica spectrum disorders. The application includes pharmaceutical compositions and methods of treatment, with animal and clinical test results demonstrating safety and efficacy. This represents an early-stage IP filing with no immediate compliance implications for the pharmaceutical sector.

Niclosamide Induces PRX1 Stem Cell Proliferation

USPTO published Patent Application US20260108480A1 on April 23, 2026, filed September 25, 2023, covering methods of inducing proliferation of PRX1-expressing stem cells using niclosamide or its pharmaceutical derivatives. The application names Giuseppe Intini, Luigi Mancinelli, and Xue Hui Geng as inventors. CPC classifications include A61K 31/167, A61K 31/352, A61K 31/4709, and A61P 19/08.

Pregabalin Tablet Treats Neuropathic Pain in Canines

USPTO published patent application US20260108484A1 for a veterinary tablet immediate-release formulation comprising approximately 25% by weight of pregabalin, 5-15% meat flavour, 58-69% microcrystalline cellulose, and 1-2% magnesium stearate as a lubricant, designated for treating neuropathic pain in non-human animals (canines). The application was originally filed on September 8, 2023 (Application No. 19116857) by TriviumVet Designated Activity Company. For pharmaceutical manufacturers, animal health companies, and veterinary drug developers, this publication establishes the priority date and claims scope for freedom-to-operate analysis.

Multi-Modal Nanoprobe Detects Atherosclerotic Plaques

The Sixth Medical Center of Chinese PLA General Hospital filed US Patent Application 19336412 on September 22, 2025, for a multi-modal molecular imaging nanoprobe designated Fe3O4-A12-Cy7. The probe combines fluorescence imaging (FLI), magnetic particle imaging (MPI), and computed tomography angiography (CTA) for early detection and dynamic monitoring of atherosclerotic plaques. Named inventors include Yundai Chen, Mingrui Ma, Yingqian Zhang, Suhui Zhang, Wei Tong, Rundou Chen, Hao Zhou, Zhongxuan Li, and Ziqian Wang.

Cofilin-1 Peptide Drug Enhances Cancer Cell Uptake

The USPTO published patent application US20260108640A1 for a cofilin-1 peptide composition designed to enhance cellular uptake in cancer cells. The peptide mimics endogenous cofilin-1 and incorporates transmembrane amino acid sequences to improve drug delivery, affecting cancer cell migration and invasion while enabling conjugation with chelators for diagnostic imaging. Filed October 22, 2024 under application number 18923581 by inventors Yi-Jang Lee, Min-Ying Lin, Chun-Yi Wu, and Jyh-Der Leu.

Exosome Tracer Complex With Gallium-67/68 Radionuclide and DOTA Chelating Agent

The USPTO published patent application US20260108642A1 on April 23, 2026, disclosing an exosome-based tracer complex incorporating gallium-67 or gallium-68 radionuclides chelated to a bifunctional chelating agent, preferably DOTA. The application was originally filed on December 5, 2024, under application number 18969548, with six inventors named. The invention is classified under A61P 25/28 (CNS disorders) and A61P 35/04 (cancer metastasis), suggesting potential diagnostic imaging applications for neurological conditions and oncology.

Patent for Treating MASLD and MASH Using OCT4, SOX2, KLF4

The USPTO published patent application US20260108630A1 on April 23, 2026, disclosing methods for treating metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH) by administering one or more nucleic acids encoding OCT4, SOX2, and KLF4 transcription factors. The application claims the administration may rejuvenate hepatocytes or liver stellate cells and improve symptoms of the liver disease. The four named inventors are Sharon Rosenzweig-Lipson, Ming Yang, Richard Davis, and Michel Wathier, with Application No. 19360504 filed on October 16, 2025.

Spontaneous Metastasis Model Method, 100% mLN Rate

US20260108632A1 is a published patent application disclosing a method for producing a spontaneous metastasis model using recombinant carcinoma cells engineered with luciferase-based expression systems. The disclosed models achieve approximately 100% metastasis incidence for mesenteric lymph node (mLN) invasion and 80–90% for secondary organs, providing statistically significant and robust kinetic data. The application was filed on October 18, 2022, under application number 18292945, with ten named inventors including Amit Sharma and colleagues.

US20260108454A1: Innate Targeting of Adoptive Cellular Therapies

USPTO published patent application US20260108454A1 (filed October 30, 2025) for therapeutic methods involving specific repertoires of PRR ligands to provoke innate immune system signaling and facilitate homing of adoptive immune cells to disease sites, particularly solid tumors. The application names inventors Harold David Gunn, David W. Mullins, Mark Bazett, and Shirin Kalyan. This is a publication of a pending application, not a granted patent.

NIHON SHOKUHIN KAKO Resident Skin Flora Improving Agent

USPTO published patent application US20260108447A1 for a resident-skin-flora-improving agent using sophorose, filed by NIHON SHOKUHIN KAKO CO., LTD. on October 2, 2023. The application discloses that sophorose promotes proliferation of beneficial skin bacteria while suppressing growth of bacteria that could adversely affect the skin, and can be used to maintain balance of resident skin flora.

Methods for Preventing Cardiovascular Events Through PCSK9 Reduction Using RNAi Agents

USPTO published patent application US20260108631A1 filed by inventors David KALLEND and Peter WIJNGAARD on December 22, 2025, covering methods for preventing cardiovascular events through PCSK9 reduction using RNAi agents. The application claims methods of lowering LDL cholesterol, preventing cardiac events in subjects with atherosclerotic cardiovascular disease, and treating such subjects by administering prophylactically or therapeutically effective amounts of an RNAi agent. CPC classifications span A61K (medicinal preparations containing genetic material), C07H (nucleosides/nucleotides), and C12N (mutation/genetic engineering).

L-Ergothioneine Gold Nanoparticles For Medical Applications

Guangzhou First People's Hospital has filed USPTO patent application US20260108633A1 for L-ergothioneine-gold nanoparticles (EGT-AuNPs) combining gold nanoparticle imaging contrast with L-ergothioneine antioxidant properties. The application covers contrast agents and antioxidants for medical imaging and renal protection, particularly early diagnosis and treatment of acute kidney injury (AKI). CPC classifications include A61K 49/04, A61K 9/5192, A61K 31/4172, and A61P 13/12, indicating pharmaceutical compositions for kidney therapy and diagnostic imaging applications.

Epinephrine Prodrug Oral Delivery Patent Application

Aquestive Therapeutics, Inc. has filed US Patent Application US20260108458A1 covering methods of treating allergic symptoms through oral administration of epinephrine and its prodrugs, claiming pharmacokinetic parameters that are improved or comparable to intramuscular injection. The application names Stephen Paul Wargacki, Alexander Mark Schobel, and Carl Neil Kraus as inventors, with a filing date of October 23, 2025. Pharmaceutical companies developing epinephrine delivery formulations should monitor this IP filing for potential freedom-to-operate implications.

Modified Cells Resist Steroid, Calcineurin Inhibitors

The USPTO has published patent application US20260108610A1 for modified cells designed to resist steroid and calcineurin inhibitor drugs, with inventors Mark J. Osborn, Keli Hippen, and Bruce R. Blazar named in the filing. The application covers pluripotent stem cells, hematopoietic precursor cells, and hematopoietic cells (including modified Tregs) with resistance mechanisms to immunosuppressive drugs. The application was filed June 30, 2025 and published April 23, 2026.

Beta-Peptide Hydrogel Therapeutic Cargo Patent Application

The USPTO has published patent application US20260108612A1 for beta-peptides and beta-peptide hydrogels with therapeutic cargo. The application, filed May 17, 2023 under application number 18865896, names nine inventors and was published April 23, 2026. The invention covers hydrogels that may encapsulate therapeutic cargo for drug delivery or biomedical applications.

GvHD Treatment Methods Using IL-22 Dimer

USPTO published patent application US20260108616A1 covering methods for treating graft versus host disease (GvHD) by administering a composition comprising an IL-22 dimer, optionally combined with immunosuppressive therapy, across multiple treatment cycles separated by rest periods. Inventors William DALEY and Xiaoqiang YAN filed the application on December 19, 2025; the application was published on April 23, 2026.

Viral Infection Treatment Conjugates with Neuraminidase Inhibitors

US20260108618A1 covers compositions and methods for treating viral infections using conjugates containing neuraminidase inhibitors (zanamivir, peramivir, or analogs) linked to an Fc monomer, Fc domain, Fc-binding peptide, albumin protein, or albumin-binding peptide. The application was filed on July 23, 2025, under application number 19277976. Inventors include Allen Borchardt, Thomas P. Brady, Zhi-Yong Chen, Thanh Lam, and Leslie W. Tari. CPC classifications include A61K 47/68, A61K 47/6803, A61P 31/16, and C07D 309/28, indicating pharmaceutical and chemical therapeutic compositions.

Single-Chain Fragment Variable Targeting KRAS G12V CAR T-Cell Therapy

USPTO published patent application US20260108609A1 on April 23, 2026, filed May 31, 2024, for a single-chain fragment variable (scFv) targeting KRAS G12V and a chimeric antigen receptor (CAR). The invention modifies a T cell receptor to recognize KRAS G12V mutant polypeptides presented by HLA-A*02:01, retaining the extracellular signaling domain linked to a CD3ζ-derived intracellular signaling domain for potential tumor treatment applications including CAR-T and NK cell therapy.

Treatment of Autoimmune Diseases Having a Pathogenic T Cell State

The Brigham and Women's Hospital, Inc. filed patent application US20260108606A1 on October 23, 2025, covering methods of treating autoimmune and inflammatory diseases by targeting pathogenic immune cell states. Inventors Ana Carrizosa Anderson and Davide Mangani disclosed novel gene dependencies in pathogenic immune cells and methods for modifying immune cells characterized by that state. CPC classifications span A61K, A61P 37/06, C12N 15/85, and C12N 2800/107.

CD5 CAR Immune Cells for Cancer Treatment

The USPTO has published patent application US20260108608A1, filed October 4, 2023, for CD5-targeting chimeric antigen receptor (CAR) immune cells co-expressing OX40 ligand and IL-15. The application claims immune cells demonstrating synergistic tumor cell-killing activity with improved viability and in vitro proliferation rates as an anticancer cell therapy. Inventors include Seung Min Kim, Eunsol Lee, Hyun Seung Sun, Hansol Kim, Sunglim Cho, Miyoung Jung, and Bokyung Min. The claimed composition is directed to treating CD5-positive tumors including lymphocytic leukemia.

Immune Cell Conjugates and Methods for Producing and Using the Same

Sandigene Inc. has published US Patent Application US20260108621A1, filed October 16, 2025 under Application No. 19360236, covering surface-modified immune cells with covalently bound linkers and non-antibody ligands selective to target-cell receptors. The application names Yanwen Fu, Reyna Koreen V. Lim, Changyou Lin, and Moli Liu as inventors. The patent covers applications in anticancer therapeutics (CPC: A61P 35/00) and cell production methods (CPC: C12N 5/0006).

US20260108627A1 mRNA Lipid Nanoparticle Compositions for Hypercholesterolemia and Cardiovascular Disease Treatment

The USPTO published application US20260108627A1 on April 23, 2026, disclosing compositions and methods for treating hypercholesterolemia and/or cardiovascular disease using lipid nanoparticle delivery systems for mRNA-based therapeutics. The application names six inventors: Fuxin Shi, Wenhu Cao, Ye Chen, Huanle Liu, Han Qiu, and Leqi Liao, with a filing date of September 21, 2023. CPC classifications include A61K 48/005, A61P 3/06, C12N 9/226, and C12N 15/111, indicating lipid nanoparticle formulations and gene therapy approaches.

Cationic Lipid Compositions for Tissue-Specific Delivery

USPTO published patent application US20260108623A1 filed by Shikha Mishra and Xavier De Mollerat Du Jeu on December 10, 2025. The application covers cationic lipid compositions for delivering bioactive agents—therapeutic or diagnostic—specifically to spleen tissue, using lipid aggregates that do not require biomolecular targeting. The compositions include cationic lipids, helper lipids, and a biostability enhancing agent.

Bispecific CARs Targeting CD20 BCMA, AbelZeta, Autoimmune, Cancer

AbelZeta Inc. filed US Patent Application US20260108557A1 for a bispecific chimeric antigen receptor (CAR) targeting both CD20 and BCMA antigens simultaneously. The CAR construct comprises an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The application was filed on October 13, 2025, and published on April 23, 2026, with claims directed to methods of treating autoimmune disorders and cancer using the disclosed CAR.

Bifidobacterium Longum Subsp. Infantis BI03 Strain for Alleviating Parkinson's Disease

The USPTO has published application US20260108568A1 for a Bifidobacterium longum subsp. infantis BI03 strain (CGMCC No. 24473, deposited March 7, 2022) for alleviating Parkinson's disease. The application claims the strain can alleviate Parkinson's-related dyskinesia and corticosterone elevation, weaken associated neuroinflammation, promote glutathione, and reduce brain oxidative stress damage. Inventors include Shuguang FANG, Yao DONG, Yixuan FAN, Zhonghui GAI, and Jianguo ZHU; the application was filed May 27, 2024.

EGFR Inhibitors for Treatment-Resistant Non-Small Cell Lung Cancer

USPTO has published patent application US20260108524A1 for methods of treating treatment-resistant non-small cell lung cancer using EGFR inhibitors. The application, filed October 16, 2023, names David A. Nathanson, Jonathan Tsang, and Timothy F. Cloughesy as inventors. CPC classifications include A61K 31/519, A61K 31/517, and A61P 35/00. This publication represents new intellectual property activity in the targeted oncology space.

FGF21 GLP1 Double Gene-Modified Mesenchymal Stem Cell Patent Application for Metabolic Disease Treatment

The USPTO published patent application US20260108558A1, filed August 21, 2025, covering a modified mesenchymal stem cell engineered to co-express FGF21 and GLP-1 proteins, intended for treating metabolic diseases. The application names inventors Haifeng DUAN, Binghua XUE, Jing XIE, and Zhenli ZHANG, and specifies CPC classifications including A61K 35/28, A61P 3/10, C07K 14/50, C07K 14/605, and various C12N cellular-therapy classifications. Publication of this application creates prior art that may affect freedom-to-operate analyses for parties developing related cellular-therapy approaches for metabolic disease.

Methods of Treating Fibromyalgia With Psilocybin Compositions - Tryp Therapeutics

Tryp Therapeutics Inc. filed patent application US20260108545A1 with the USPTO on September 11, 2023 (application no. 19110772), published April 23, 2026. The application covers methods for treating fibromyalgia using psychedelics such as psilocybin or metabolites thereof, optionally combined with psychotherapy, with patient outcomes assessed through observer-rated and subject-reported measures as well as biological and clinical indicators. The inventors are James GILLIGAN and Peter GUZZO. Pharmaceutical and biotech companies pursuing psychedelic-based therapeutic research should monitor this filing as it may affect competitive patent positioning in fibromyalgia treatment.

US20260108572A1 - Alzheimer's Dementia Suppressant Using Sesamum Indicum Extract

USPTO published patent application US20260108572A1, filed September 1, 2023 and made publicly available on April 23, 2026, disclosing an Alzheimer-type dementia suppressant composition and method of manufacture using an aboveground part of Sesamum indicum (sesame plant) or an extract thereof as the active ingredient. The application names Sakamoto Yakusouen, LLC as assignee and Johji YAMAHARA as inventor. CPC classifications include A61K 36/185, A61K 31/7048, A61P 25/28, and related formulation codes A61K 2236/17, A61K 2236/333, A61K 2236/51, and A61K 2236/53. The application does not yet represent an issued patent and carries no compliance obligation.

Anti-Cancer Therapy Methods Using Autophagy Induction via DBI Inhibition

USPTO published patent application US20260108602A1 covering methods and systems for improving anti-cancer therapies through autophagy induction via inhibition of extracellular diazepam binding inhibitor (DBI). Inventors include Mark de Boer, Guido Kroemer, Léa Montegut, Isabelle Martins, Hui Pan, Hui Chen, and Sijing Li, with application number 19361314 filed October 17, 2025. The application claims therapeutic compositions, methods, and regimens for cancer treatment, including chemo- and immunotherapies.

Engineered Immune Effector Cell with CD16 Protein for Shear Resistance

USPTO published patent application US20260108605A1, filed September 27, 2023, covering a genetically modified immune effector cell expressing a recombinant human CD16 protein engineered with amino acid additions, deletions, and replacements that confer enhanced shear resistance. The application names five inventors: Fuwei JIANG, Tingting LIU, Yifang WANG, Cuiqing YANG, and Zhuoxiao CAO. CPC classifications span immunology (A61K 38/1774, A61K 39/39558), oncology (A61P 35/00), and protein engineering (C07K 14/7051, C07K 16/2803).

Probiotic Preparation Containing Akkermansia Muciniphila Akk11 Strain for Alleviating Hypertension

USPTO published patent application US20260108565A1 on April 23, 2026, covering a probiotic preparation combining Akkermansia muciniphila Akk11 strain with Lactobacillus rhamnosus LRa05 strain for alleviating hypertension. The application, originally filed July 9, 2024 under application number 18879015, names Shuguang Fang, Yao Dong, Yunjiao Zhao, Zhonghui Gai, and Jianguo Zhu as inventors. The CPC classifications include A61K 35/741, A61P 9/12, and A61K 2035/115, indicating pharmaceutical preparations containing probiotics and anti-hypertensive agents.

Mycobacteriophage Compositions and Related Methods, Oregon State University

USPTO published patent application US20260108571A1 for Oregon State University on April 23, 2026, covering isolated bacteriophages with lytic activity against mycobacterial species, including the specific phage Pill582 and variants thereof. The application (filed 2025-10-20, Application No. 19363116) discloses phage cocktails, pharmaceutical compositions, and methods for treating mycobacterial infections and associated disease conditions.

University of Chicago Bacteriophage Patent for Bacterial Infections

The University of Chicago has received a published patent application (US20260108570A1) for bacteriophage compositions and methods targeting Enterobacteriaceae infections, including Klebsiella. The application, filed August 1, 2023, covers isolated bacteriophage sequences with at least 99% identity to SEQ ID NO:1-74, along with associated devices, kits, and treatment methods. Inventors include Mark MIMEE and Ella ROTMAN.

Anti-IL6 Receptor Antibody Treats Rheumatoid Arthritis

USPTO published patent application US20260108601A1 on April 23, 2026, filed September 22, 2025, covering methods of treating rheumatoid arthritis using an anti-IL6 receptor antibody in subjects with specific serum biomarker concentrations. The application names Anita Boyapati, Jérôme Msihid, and Moshe E. Zilberstein as inventors. Pharmaceutical and biotechnology companies developing IL-6 targeted therapies for autoimmune conditions may wish to monitor this application's prosecution for potential freedom-to-operate considerations.

Compound Emulsion Injection for Nausea and Vomiting

The USPTO published patent application US20260097042A1 for a compound emulsion combining aprepitant and palonosetron hydrochloride for injection. The formulation claims improved stability and enhanced patient adherence in preventing and treating nausea and vomiting. The application was filed on May 30, 2025.

Compositions and Methods for IV Administration of ABDNAZ for Cancer Treatment

USPTO published patent application US20260097013A1 for compositions and methods for intravenous administration of ABDNAZ (2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone) for cancer treatment. The application, filed on 2025-06-11, covers formulations containing autologous whole blood and ABDNAZ for rapid IV infusion. Inventors: Bryan T. Oronsky, Jan Scicinski, and Scott Caroen.

Epoxytiglienone Compounds for Disrupting Gram-negative Bacterial Biofilms

The USPTO has published patent application US20260097011A1 for epoxytiglienone compounds designed to disrupt biofilms comprising Gram-negative bacteria. The application covers methods of dispersing established biofilms through localized administration, including topical or injection delivery, as well as methods for preventing biofilm formation on medical devices. Inventors include David William Thomas, Paul Warren Reddell, Glen Mathew Boyle, and others. The application was filed on December 2, 2025.

Compounds and Combinations Thereof for Treating Neurological and Psychiatric Conditions

The USPTO published patent application US20260097006A1 by inventor Herriot Tabuteau, filed September 4, 2025, covering compounds and combinations containing dextromethorphan for treating neurological and psychiatric conditions. The application discloses dosage forms and drug delivery systems typically combined with antidepressants such as bupropion. This publication makes the application publicly available for review and potential opposition.

CHIMERIC ANTIGEN RECEPTOR SPACERS

The USPTO published Lyell Immunopharma's patent application US20260098075A1 for chimeric antigen receptors (CARs) incorporating immunoglobulin-derived spacers, such as hinge or loop regions, designed to enhance cytokine release compared to CARs with non-Ig-derived spacers. The spacers may be derived from human immunoglobulins (IgAQ1, IgA2, IgD, IgE, IgG1-4, IgM) or non-human sources (e.g., mouse IgG2A), and may be configured as modular constructs combining multiple Ig hinges or fragments thereof. Filed September 8, 2025.

Rapid Conjugate Vaccine Manufacturing Method, Inventprise

Rapid Conjugate Vaccine Manufacturing Method, Inventprise

Oncolytic Vaccinia Viruses and Recombinant Viruses and Methods of Use Thereof

The USPTO published patent application US20260097116A1 by ViroMissile, Inc. covering clonal strains of vaccinia virus engineered as oncolytic virus therapies for treating cancer. The application includes claims for recombinant vaccinia viruses with inactivating mutations and heterologous gene products, pharmaceutical compositions, and methods of use for anti-tumor therapy.

CD19/CD22 CAR T Cell Treatment for High-Risk Pediatric Acute Lymphoblastic Leukemia

The USPTO published patent application US20260097122A1 for CD19/CD22 chimeric antigen receptor (CAR) T-cell products and methods for treating high-risk or relapsed CD19+ or CD22+ haematological malignancies, specifically pediatric acute lymphoblastic leukemia. The application was filed on May 10, 2023, under application number 18862269. Inventors include Martin Pulé, Persis Amrolia, and Sara Ghorashian.